Closely-held Viz.ai raised $100-million to expand its artificial-intelligence platform designed to detect and triage strokes, heart attacks and aneurysms by scanning patient imagery.
The Series D funding round led by Tiger Global Management and Insight Partners raises the company’s valuation to $1.2-billion.
“Viz.ai is committed to helping patients get better, faster and more equitable access to life saving treatments,” Chris Mansi, M.D. and CEO of Viz.ai, said in a statement.
“We will continue to invest heavily in cutting edge technology and services to integrate deeply into the clinical workflow, allowing us to automate disease detection, increase diagnostic rates and enhance workflows across the entire hub-and-spoke health system,” he added. “More patients receive the right treatment, resulting in better patient outcomes and improved financial efficiency for the health system.”
Viz.ai is creating a synchronized system of action for hospitals that delivers critical diagnostic data at decision-making moments and is clinically validated to improve patient care. Viz.ai solves the fundamental problem of connecting radiologists, emergency physicians, and primary care practitioners to the optimal specialists for a particular disease in order to facilitate care coordination and ensure optimized and consistent care pathways, reducing variability.
The funding announcement follows the launch of the company’s AI-driven life science platform, a first-of-its-kind solution that revolutionizes the way medical device and pharmaceutical companies perform clinical trials and bring their treatments to market.
